This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Diabetes
  • /
  • Semaglutide: First Global Approval.

Semaglutide: First Global Approval.

Read time: 1 mins
Published:1st Feb 2018
Author: Dhillon S.
Source: Drugs
Availability: Pay for access, or by subscription
Ref.:Drugs. 2018 Feb;78(2):275-284.

Novo Nordisk has developed a subcutaneous formulation of semaglutide (Ozempic®), a modified human glucagon-like peptide-1 (GLP-1) analogue, for the treatment of type 2 diabetes mellitus. It has been developed using Novo Nordisk's proprietary protein-acylation technology, and is administered using an injection device. Semaglutide lowers blood glucose by stimulating the release of insulin and also lowers body weight. Once-weekly subcutaneous semaglutide has recently been approved in the US, Puerto Rico and Canada, and has received a positive opinion in the EU for the treatment of patients with type 2 diabetes. It will be launched as the Ozempic® Pen, a pre-filled device. Semaglutide is also under regulatory review in Japan and Switzerland for the treatment of type 2 diabetes. Clinical development for obesity, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease is underway worldwide. This article summarizes the milestones in the development of semaglutide leading to this first approval for type 2 diabetes.


Read abstract on library site

Access full article